Clinical TrialsThe updated Phase 2a data continues to demonstrate an improved clinical profile, both on efficacy and safety, for the combo in first-line pancreatic cancer patients compared to GnP alone.
Drug EfficacyIMM-1-104 plus chemotherapy combinations in pancreatic cancer have demonstrated approximately 50% objective response rate higher than the current standard of care.
PartnershipsPartnering with a global pharmaceutical company like Regeneron provides external validation of Immuneering's technology.